Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Alden

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Toxicologic Pathology|April 5, 2005
Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicityMollisa M Elrick, Jeffrey A Kramer, Carl L Alden, et al.
Journal of Behavioral Medicine|August 28, 2016
What is a good medical decision? A research agenda guided by perspectives from multiple stakeholdersJada G Hamilton, Sarah E Lillie, Dana L Alden, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Veterinary Pathology|March 6, 2009
Veterinary pathology and peer reviewG H Cantor, J L Caswell, J W Crissman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancerA Di Federico, S L Alden, J W Smithy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Cancer Research Communications|September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor TherapyHoward L Li, Soren Charmsaz, Mari Nakazawa, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Toxicologic Pathology|April 5, 2005
Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicityMollisa M Elrick, Jeffrey A Kramer, Carl L Alden, et al.
Journal of Behavioral Medicine|August 28, 2016
What is a good medical decision? A research agenda guided by perspectives from multiple stakeholdersJada G Hamilton, Sarah E Lillie, Dana L Alden, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Veterinary Pathology|March 6, 2009
Veterinary pathology and peer reviewG H Cantor, J L Caswell, J W Crissman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2024
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancerA Di Federico, S L Alden, J W Smithy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Cancer Research Communications|September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor TherapyHoward L Li, Soren Charmsaz, Mari Nakazawa, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 12